Skip to main content
. 2008 Oct 6;3(10):e3319. doi: 10.1371/journal.pone.0003319

Figure 3. Frequency and mRNA of CD4+Foxp3+ T regulatory cells are not altered by Natalizumab therapy.

Figure 3

(A) The frequency of CD4+Foxp3+ Tregs was determined by flow cytometry before and 30 days after the first infusion. (B) Foxp3 mRNA expression levels as analyzed by real-time PCR before and 3 months after initiation of therapy (nā€Š=ā€Š5).